Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic... (o thegrowing list of mRNA and microRNA d...)

HOME >> BIOLOGY >> TECHNOLOGY

Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders

Date:8/24/2009

o the growing list of mRNA and microRNA drug discovery and development partnerships that include Wyeth (delivery of lead candidates against up to ten mRNA and microRNA targets), GlaxoSmithKline (four viral disease drug candidates) and Enzon Pharmaceuticals (eight cancer targets successfully delivered).

About Locked Nucleic Acid (LNA) Drug Platform

The Locked Nucleic Acid (LNA) Drug Platform developed by Santaris Pharma A/S creates synthetic chemical versions called LNAs of the normal nucleic acid building blocks of ribonucleic acids (RNA). These LNAs improve the drug-like qualities of resulting therapeutics, called oligonucleotides, by boosting resistance to metabolism, increasing half-life and improving tissue uptake. LNA-based therapeutics demonstrate improved binding affinity to their target RNA, which increases potency many-fold over other nucleotide therapeutics. The greater potency of LNA in binding complementary RNA sequences also allows for the use of significantly shorter LNA oligonucleotide drugs which can be more effective than previous antisense or siRNA drugs.

About Santaris Pharma A/S

Santaris Pharma A/S is a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs. Utilizing the Company's proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S provides fast and efficient generation of lead LNA drug candidates. The Company's own research and development activities focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, rare genetic disorders and inflammatory diseases. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the US. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Wyeth Pharmaceut
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
2. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
3. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
4. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
5. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
8. Pre-Owned Prices on Premium Pharmaceutical Equipment
9. Laureate Pharma Elects New Board Member
10. CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress
11. PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry

Post Your Comments:

(Date:12/16/2009)... /PRNewswire/ -- Capitalizing on the continued ... an active venture capital market, leaders from BioCrossroads, ... Fund, Indiana University, Purdue University, the University of ... Suisse today announced the establishment of the INext ... funds. ,, Organized through BioCrossroads, Indiana,s initiative to ...

(Date:12/16/2009)... company,s revenues increase 22% for fiscal 2009; on ... , TORONTO, Dec. 16 /PRNewswire-FirstCall/ - Microbix Biosystems ... and biological technologies, today reported financial results for ... year ended September 30, 2009, Microbix reported revenues ... same period in 2008. For fourth-quarter 2009, the ...

(Date:12/16/2009)... Trial conducted pursuant to Special Protocol Assessment ... QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna ... AEZ) (the "Company"), a global biopharmaceutical company ... announced the initiation, by its partner Keryx ... Phase 3 registration clinical trial for perifosine ...

(Date:12/16/2009)... Eppendorf has initiated an,import ban for Nanosphere, ... of European patent EP 1 179 180 ... quantification of a target compound". The import,ban ... respective products into any country of,the European ... any,violating products. , ...

Breaking Biology Technology:Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2 Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3 Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4 Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5 Microbix' Pipeline Set To Reach Milestones In 2010 2 Microbix' Pipeline Set To Reach Milestones In 2010 3 Microbix' Pipeline Set To Reach Milestones In 2010 4 Microbix' Pipeline Set To Reach Milestones In 2010 5 Microbix' Pipeline Set To Reach Milestones In 2010 6 Microbix' Pipeline Set To Reach Milestones In 2010 7 Microbix' Pipeline Set To Reach Milestones In 2010 8 AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2 AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3 AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4 AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5 Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2

[0] Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth [0] Microbix' Pipeline Set To Reach Milestones In 2010 [0] AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma [0] Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union

... security guards came to the DHS Science and Technology Directorates ... list was an emergency escape hood worthy of James Bond: ... pound, folding to the dimensions of a DVD case, and ... must be maintenance-free, filter nerve, blood, and blister agents, remove ...

... SUNNYVALE, Calif., April 21 /PRNewswire-FirstCall/-- Pharmacyclics,Inc. (Nasdaq: ... Nasdaq staff,deficiency letter on April 17, 2008 indicating ... price for Pharmacyclics, common stock has closed,below the ... share for continued,inclusion on The Nasdaq Global Market ...

... $18.9 Million Net Revenues, $0.03 Net Loss Per Share, ... Inc. (Nasdaq: VNUS ), a leading provider of ... today announced its,financial results for the first quarter ended ... quarter of 2008 increased 21% to $18.9,million compared with ...

Other Biology Technology:Boys in the Hood 2 VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 2 VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 3 VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 4 VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 5 VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 6 VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 7

Boys in the Hood Pharmacyclics Announces It Received Nasdaq Notification VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales

(Date:12/16/2009)... seasonal exposure to pesticides in rivers and basins ... salmon populations. In addition to the widespread deterioration ... to commonly used pesticides may further inhibit the ... "Major efforts are currently underway to restore Pacific ... populations," says David Baldwin of the National Oceanic ...

(Date:12/16/2009)... Dec. 1 GestureTek Inc. today ... 3.0 - a turnkey, portable, plug and ... exhibits, entertainment and touring promotions. GestureTek is ... patents in camera-enabled gesture recognition technology for ... Guaranteed for quality, the CUBE has TUV, ...

(Date:12/16/2009)... 2009 National Instruments (Nasdaq: ... and control, and DENSO Robotics, a leader ... technology, today announced their collaboration to integrate ... robotic arms. The collaboration increases productivity and ... manufacturing applications. In today,s trend toward high-mix, ...

Breaking Biology News(10 mins):Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3 National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2 National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3 National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4 National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5 Baylor University Medical Center at Dallas Recognized for Exemplary Surgical Patient Care 58634 1 Baylor University Medical Center at Dallas Recognized for Exemplary Surgical Patient Care 58634 2 Baylor University Medical Center at Dallas Recognized for Exemplary Surgical Patient Care 58634 3 iTech Medical Provides Update on MPR Clinical Development Plan 58632 1 iTech Medical Provides Update on MPR Clinical Development Plan 58632 2 iTech Medical Provides Update on MPR Clinical Development Plan 58632 3 iTech Medical Provides Update on MPR Clinical Development Plan 58632 4 Largest Survey of Its Kind Finds the Psychological and Social Effects of Psoriasis Greater for Women 58630 1 Largest Survey of Its Kind Finds the Psychological and Social Effects of Psoriasis Greater for Women 58630 2 Largest Survey of Its Kind Finds the Psychological and Social Effects of Psoriasis Greater for Women 58630 3

[0] Even at sublethal levels, pesticides may slow the recovery of wild salmon populations [0] GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits [0] National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics

... during a long-distance race may do serious harm rather ... too much, according to a cardiologist at UT Southwestern ... drink too much water during a race could put ... by a loss in the body's sodium content that ...

... of scientists led by biophysicist Stuart Lindsay from ... created the first reproducible single molecule negative differential ... groundbreaking experimental technique that provides a “roadmap?for designing ... were presented Feb. 18 by Lindsay at the ...

... today the launch of the new GeneChip(R) Globin-Reduction ... PreAnalytiX -- a joint venture between QIAGEN N.V. ... (Becton, Dickinson and Company). The new kits optimize ... with Affymetrix GeneChip technology and improve gene expression ...

Other Biology News:Bush, Cheney and Rumsfeld are now species of slime-mold beetles -- but strictly in homage 2 Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics 2 Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics 3 Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 2 Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 3

Bush, Cheney and Rumsfeld are now species of slime-mold beetles -- but strictly in homage Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX

Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...

1/4" to 1/8" Adapter for Reflectance Probe Holder...

... Glucagon-like peptide-1(7-36) amide (GLP-1), C-terminal ... but shows <0.1% cross reactivity with ... or other related peptides such as ... Most mammalian species. GLP-1 is identical ...

Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...

Biology Products:

Mouse Anti-Angiotensin II Type 1 Receptor Monoclonal Antibody, Unconjugated, Clone TONI-1 from Abcam 1/4" to 1/8" Adapter for Reflectance Probe Holder from Ocean Optics Anti-GLP-1 (7-36) (Glucagon-like peptide-1), C-terminus amide-reactive Polyclonal Antibody, Unconjugated from CHEMICON Goat Anti-Human / Mouse / Rat AMPK beta 1 Polyclonal Antibody, Unconjugated from R&D Systems

Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic...(o thegrowing list of mRNA and microRNA d...)